Windlas Biotech, a company in the Pharmaceuticals industry, reported revenue of ₹264 crore and net profit of ₹18 crore for the September 2026 quarter.
Windlas Biotech (NSE: WINDLAS) closed at ₹961.25 on 20 Nov 2026, up 19.5% over the past year. Its market capitalisation is ₹1,984 crore and it trades at 29.8 times earnings.
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.